ArticleNature2025
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.
Abstract read
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Adaptive mechanisms and emerging cancer therapeutics for CDK2 inhibitors.Nature chemical biology · 2026Review
- Solution Ensembles of Griselimycin Expand the Definition of Molecular Chameleonicity.Journal of medicinal chemistry · 2026Article
- NSUN2-mediated m5C modification of E2F1 promotes lung adenocarcinoma progression via the RAD54L signaling axis.Respiratory research · 2026Article
- The evolving landscape of CDK inhibitor use in breast cancer therapy and beyond.Nature reviews. Drug discovery · 2026Review
- Chicken lncRNA-9802 Induces the S Phase Arrest in the T Lymphocyte Cells Infected by Marek's Disease Virus via the TP53BP1/p53/p21 Pathway.Veterinary sciences · 2026Article
- Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy.Cancer research · 2026Review
- Synthetic lethality between RB-loss and E2F3 inhibition in small cell cancers targeted by pyrimidine synthesis blockade.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Uncovering cancer dependencies in peptide-interacting protein pockets.bioRxiv : the preprint server for biology · 2026Article
- Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.Journal of medicinal chemistry · 2026Article
- Tumor cell cycle regulation: integrated perspective of stage characteristics, regulatory networks, and signaling pathway intervention strategies.Molecular biomedicine · 2026Review
- Frontiers in Cell-Cycle-Targeting Therapies: Addressing the Heterogeneity of the Cancer Cell Cycle.Cancers · 2026Article
- The Five-Decade Journey of Small Cell Lung Cancer.Cancer communications (London, England) · 2026Review
- Identification of RFC5 as a potential prognostic biomarker in diffuse large B-cell lymphoma: a combined bioinformatics and immunohistochemical study.Discover oncology · 2025Article
- A functional map of CDK-drug interactions at single amino acid resolution.bioRxiv : the preprint server for biology · 2025Article
- Discovery of Cell-Permeable Macrocyclic Cyclin A/B RxL Inhibitors that Demonstrate Antitumor Activity.Journal of medicinal chemistry · 2025Article
- Histone-related gene WDR77 promotes tumor progression through cell cycle regulation in skin cutaneous melanoma.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
59 authors.
Shilpa SinghDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Catherine E GleasonCircle Pharma, San Francisco, CA, USA.ORCID 0000-0002-0063-0729
Min FangDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yasmin N LaimonDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-0848-9843
Vishal KhivansaraDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Shanhai XieDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Yavuz T DurmazDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Aniruddha SarkarDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-9393-1335
Kenneth NgoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Varunika SavlaDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Yixiang LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Muhannad Abu-RemailehDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Xinyue LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Marie-Anais LocquetDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Bishma TuladharBelfer Center for Applied Cancer Science, Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, MA, USA.
Ranya OdehCircle Pharma, San Francisco, CA, USA.
Frances Hamkins-IndikCircle Pharma, San Francisco, CA, USA.
Daphne HeCircle Pharma, San Francisco, CA, USA.
Miles W MembrenoCircle Pharma, San Francisco, CA, USA.
Meisam NosratiCircle Pharma, San Francisco, CA, USA.
Nathan N GushwaCircle Pharma, San Francisco, CA, USA.
Siegfried S F LeungCircle Pharma, San Francisco, CA, USA.
Breena Fraga-WaltonCircle Pharma, San Francisco, CA, USA.
Luis HernandezCircle Pharma, San Francisco, CA, USA.
Miguel P BaldomeroCircle Pharma, San Francisco, CA, USA.
Bryan M LentCircle Pharma, San Francisco, CA, USA.
David SpellmeyerCircle Pharma, San Francisco, CA, USA.ORCID 0009-0002-9259-0767
Joshua F LunaCircle Pharma, San Francisco, CA, USA.
Dalena HoangCircle Pharma, San Francisco, CA, USA.
Yuliana GritsenkoCircle Pharma, San Francisco, CA, USA.
Manesh ChandCircle Pharma, San Francisco, CA, USA.
Megan K DeMartCircle Pharma, San Francisco, CA, USA.
Sammy MetoboCircle Pharma, San Francisco, CA, USA.
Chinmay BhattCircle Pharma, San Francisco, CA, USA.
Justin A ShapiroCircle Pharma, San Francisco, CA, USA.
Kai YangCircle Pharma, San Francisco, CA, USA.
Nathan J DupperCircle Pharma, San Francisco, CA, USA.
Andrew T BockusCircle Pharma, San Francisco, CA, USA.ORCID 0000-0001-5522-6523
Jinshu FangCircle Pharma, San Francisco, CA, USA.
Ramesh BambalCircle Pharma, San Francisco, CA, USA.
Peadar CreminCircle Pharma, San Francisco, CA, USA.
John G DoenchBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-3707-9889
James B AggenCircle Pharma, San Francisco, CA, USA.
Li-Fen LiuCircle Pharma, San Francisco, CA, USA.
Bernard LevinCircle Pharma, San Francisco, CA, USA.
Evelyn W WangCircle Pharma, San Francisco, CA, USA.
Iolanda VendrellTarget Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Roman FischerTarget Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-9715-5951
Benedikt KesslerTarget Discovery Institute, Centre for Medicines Discovery, Nuffield Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0002-8160-2446
Prafulla C GokhaleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1974-5921
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-5000-9105
Alexander SpektorDepartment of Radiation Oncology, Dana-Farber Cancer Institute, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-1085-3205
Constantine KreatsoulasCircle Pharma, San Francisco, CA, USA.
Marie EvangelistaCircle Pharma, San Francisco, CA, USA.
Rajinder SinghCircle Pharma, San Francisco, CA, USA.
David J EarpCircle Pharma, San Francisco, CA, USA.
Deepak NijhawanDepartment of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Pablo D GarciaCircle Pharma, San Francisco, CA, USA.
Matthew G OserDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. matthew_oser@dfci.harvard.edu.ORCID 0000-0003-2047-0969
Funding
Welch Foundation
Abstract
Small-cell lung cancers (SCLCs) contain near-universal loss-of-function mutations in RB1 and TP53, compromising the G1-S checkpoint and leading to dysregulated E2F activity
Indexed as
Cyclin AG1 Phase Cell Cycle CheckpointsLung NeoplasmsMolecular Targeted TherapyS PhaseAmino Acid MotifsAnimalsApoptosisCell Line, TumorCyclin-Dependent Kinase 2E2F Transcription FactorsFemaleHumansMaleMicePeptidesCDK2 protein, humanCyclin ACyclin-Dependent Kinase 2E2F Transcription FactorsPeptides
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.